Romosozumab의 효과 및 심혈관계 안전성 : 체계적 문헌고찰 및 메타분석
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최서용 | - |
dc.contributor.author | 김정민 | - |
dc.contributor.author | 오상현 | - |
dc.contributor.author | 천승현 | - |
dc.contributor.author | 정지은 | - |
dc.date.accessioned | 2023-08-07T07:30:58Z | - |
dc.date.available | 2023-08-07T07:30:58Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 1226-6051 | - |
dc.identifier.issn | 2508-786X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/113704 | - |
dc.description.abstract | Background: This systematic review and meta-analysis aimed to evaluate the efficacy and cardiovascular safety of romosozumab compared with placebo. Methods: Randomized controlled trials (RCTs) were searched from Medline, EMBASE, Cochrane Central, and Web of Science until July 2022. Primary outcomes included the change in bone mineral density (BMD) from baseline at month 6. The secondary outcomes were the change of bone turnover markers (N-terminal propeptide of type 1 procollagen (P1NP); C-terminal telopeptide of type 1 collagen (CTX)) from baseline at month 3, and the incidence of cardiovascular adverse events for the total follow-up period. Results: A total of 7 RCTs on 8,370patients were included. Romosozumab showed better effects in improving BMD in both lumbar spine and femoral neck at month 6 (standardized mean difference, SMD 2.20 [95% CI: 1.89-2.52], SMD 0.63 [95% CI: 0.41-0.86]). In contrast to placebo, romosozumab significantly increased PINP levels and reduced CTX levels at month 3 (SMD 0.93 [95% CI: 0.65-1.22], SMD −1.03 [95% CI: −1.23~ −0.82]. However, there was no significant difference in the composite incidence of cardiovascular adverse events and major adverse cardiovascular events (OR 1.16 [95% CI: 0.82-1.65], OR 1.08 [95% CI: 0.75-1.56]). Conclusion: This analysis showed that romosozumab significantly improved BMD compared to placebo and was beneficial for change in bone turnover markers. There is no significant difference in the incidence of cardiovascular adverse events compared to placebo. | - |
dc.format.extent | 7 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 한국임상약학회 | - |
dc.title | Romosozumab의 효과 및 심혈관계 안전성 : 체계적 문헌고찰 및 메타분석 | - |
dc.title.alternative | Efficacy and Cardiovascular Safety of Romosozumab: A Meta-analysis and Systematic Review | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.24304/kjcp.2023.33.2.128 | - |
dc.identifier.bibliographicCitation | 한국임상약학회지, v.33, no.2, pp 128 - 134 | - |
dc.citation.title | 한국임상약학회지 | - |
dc.citation.volume | 33 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 128 | - |
dc.citation.endPage | 134 | - |
dc.identifier.kciid | ART002975857 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Bone mineral density (BMD) | - |
dc.subject.keywordAuthor | cardiovascular diseases (CVDs) | - |
dc.subject.keywordAuthor | CTX | - |
dc.subject.keywordAuthor | osteoporosis | - |
dc.subject.keywordAuthor | romosozumab | - |
dc.identifier.url | https://www.earticle.net/Article/A431786 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.